Mayer IA, Zhao F, Arteaga CL, et al. - Researchers conducted the EA1131 trial with the aim to test the hypothesis that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype triple-negative breast cancer (TNBC) treated with adjuvant platinum compared with capecitabine. They randomly assigned 410 of the planned 775 participants to receive platinum (carboplatin or cisplatin) once every 3 weeks for four cycles or capecitabine 14 out of 21 days every 3 weeks for six cycles. Patients with basal subtype TNBC residual invasive disease post-neoadjuvant chemotherapy (NAC) did not show improvement in outcomes in correlation with receiving platinum agents and more severe toxicity was observed linked with these agents when compared with capecitabine. A lower than expected 3-year iDFS was observed among participants regardless of study treatment, highlighting the necessity for better therapies in this high-risk population.